Skip to content
x.com· @ · X·· 2026-04-22Score60

#COLORECTAL

Reading

KRAS / RAS targeting: from platform to Phase 3

Body

#AACR26 Day 5🚀

💥Early-onset cancers
🗣️@AndyChanMD @MassGenBrigham

📌Early-onset #colorectal cancer
🔹Chronic inflammation
🔹Epigenetic changes prime tumor growth
🔹 Obesity, Diabetes, chronic inflammation, disbiosis

Very interesting #research

@OncoAlert @AACR @CRC_AACR https://t.co/ACCwTiyxjf

Heat 10 · 6 likes · 1 reply · 3 reposts

Conference abstracts
CT152NCT06885385matched by 摘要号 CT152
Preliminary results from a phase II trial evaluating the safety and efficacy of JS207, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic colorectal cancer

Yong Gao, Zhiwei Li, Jianwei Yang, Shuqing Jin, Yiyi Yu, Chang Wang, Xiwen Huang, Jingdong Zhang, Yanhong Gu, Shuqin Ni, Yanlai Sun, Shirong Cai, Liang Han, Xinjun Liang, Haichuan Su, Chenxi Wang, Zhenyu Xu, Jing Xu, Chengbo Jia, Jianjun Zou, Lin Shen

Read the abstract →
CT216NCT05379595NCT06750094matched by 药名 cetuximab
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer

J. Randolph Hecht, Elena Élez, Cathy Eng, Peter Gibbs, Jenny Seligmann, Ruihua Xu, Kensei Yamaguchi, Jaw Yuan Wang, Hao Wei Teng, Leonardo Trani, Honeylet Wortman-Vayn, Zhengyu Jiang, Brooke Diorio, Patricia Lorenzini, Christine Baudelet, Seema Sethi, Mahadi Baig, Chiara Cremolini

Read the abstract →
CT217NCT05379595NCT06662786matched by 药名 cetuximab
OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer

Dirk Arnold, Andres Cervantes, Michel Ducreux, Sae-won Han, Heinz-Josef Lenz, Kei Muro, Kanwal Raghav, Lin Shen, Jaw Yuan Wang, Pei Jye Voon, Hung-Chuh Hsu, Bing Xia, Ryota Iwasawa, Shamita Carrigan, Brooke Diorio, Patricia Lorenzini, Sandip Acharya, Seema Sethi, Mahadi Baig, Filippo Pietrantonio

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org